Dr. Vimal Prajapati reports about tapinarof 1% cream for treating severe AD at the 2023 EADV Congress in Berlin.

Dr. Mark Kirchhof reports late breakers presentations around atopic dermatitis and prurigo nodularis from the 2023 EADV Congress in Berlin.

Dupilumab successfully decreases IgE serum levels in AD patients regardless of dosing intervals, according to a recent study.

New research shows that adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease...

A maternal high protein diet may be a risk factor for infantile AD during the first year of life.

Two reviews from researchers at McMaster University in Hamilton have identified the most effective topical and systemic treatments for...

In a recent study, researchers at National Jewish Health investigated the impact of dupilumab on the vascular barrier function in...

Dupilumab has been shown to reduce severity and improve QoL in pediatric patients with AD two weeks after treatment.